Affiliation:
1. Fuwai Hospital
2. Beijing Hospital
3. The Sixth Affiliated Hospital of Wenzhou Medical University
Abstract
Abstract
Background Existing pharmacogenetic algorithms cannot fully explain warfarin dose variability in patients. CYP2C9*13 is an important allelic variant in the Han Chinese population. However, adjustment of warfarin dosing in CYP2C9*13 variant carriers remains unclear. To the bets of our knowledge, this study is the first to assess the effects of adjusting warfarin dosages in Han Chinese patients harbouring CYP2C9*13 variants.Methods In total, 971 warfarin-treated Han Chinese patients with atrial fibrillation were enrolled in this study. Clinical data were collected, and CYP2C9*2, *3, *13 and VKORC1-1639 G > A variants were genotyped. We quantitatively analysed the effect of CYP2C9*13 on warfarin maintenance dose and provided multiplicative adjustments for CYP2C9*13 using validated pharmacogenetic algorithms.Results Approximately 0.6% of the Han Chinese population carried CYP2C9*13 variant, and the genotype frequency was between those of CYP2C9*2 and CYP2C9*3. The warfarin maintenance doses were significantly reduced in CYP2C9*13 carriers. When CYP2C9*13 variants were not considered, the pharmacogenetic algorithms overestimated warfarin maintenance doses by 1.03–1.16 mg/d on average. The actual warfarin dose in CYP2C9*13 variant carriers was approximately 40% lower than the algorithm-predicted dose. Adjusting the warfarin-dosing algorithm according to the CYP2C9*13 allele could reduce the dose prediction error.Conclusion Our study showed that the algorithm predicted doses should be lowered for CYP2C9*13 carriers. Inclusion of the CYP2C9*13 variant in the warfarin-dosing algorithm tends to predict the warfarin maintenance dose more accurately and improves the efficacy and safety of warfarin administration in Han Chinese patients.
Publisher
Research Square Platform LLC
Reference36 articles.
1. Pharmacogenetics of warfarin: challenges and opportunities;Lee MT;Journal of human genetics,2013
2. Genotype-guided warfarin therapy;Tavares LC;Current status,2018
3. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):287s-310s.
4. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions;Pirmohamed M;Annual review of genomics and human genetics,2014
5. Estimation of the warfarin dose with clinical and pharmacogenetic data;Klein TE;The New England journal of medicine,2009